News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
145,335 Results
Type
Article (7949)
Company Profile (34)
Press Release (137352)
Multimedia
Podcasts (3)
Webinars (2)
Section
Business (43500)
Career Advice (239)
Deals (5209)
Drug Delivery (15)
Drug Development (21242)
Employer Resources (35)
FDA (2588)
Job Trends (3625)
News (72036)
Policy (5211)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (2)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (2)
2024 Genetown Standard (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 Pharm Country Standard (1)
Academia (916)
Accelerated approval (1)
Adcomms (3)
Allergies (23)
Alliances (12050)
ALS (30)
Alzheimer's disease (550)
Antibody-drug conjugate (ADC) (27)
Approvals (2593)
Artificial intelligence (76)
Autoimmune disease (5)
Automation (5)
Bankruptcy (31)
Best Places to Work (3201)
BIOSECURE Act (1)
Biosimilars (19)
Biotechnology (23)
Bladder cancer (27)
Brain cancer (8)
Breast cancer (99)
Cancer (659)
Cardiovascular disease (73)
Career advice (223)
Career pathing (8)
CAR-T (43)
Cell therapy (113)
Cervical cancer (2)
Clinical research (16617)
Collaboration (240)
Compensation (33)
Complete response letters (3)
COVID-19 (701)
CRISPR (18)
C-suite (100)
Cystic fibrosis (37)
Data (798)
Denatured (1)
Depression (12)
Diabetes (67)
Diagnostics (1549)
Digital health (2)
Diversity, equity & inclusion (9)
Drug discovery (36)
Drug pricing (9)
Drug shortages (3)
Duchenne muscular dystrophy (34)
Earnings (11110)
Editorial (8)
Employer branding (7)
Employer resources (33)
Events (22627)
Executive appointments (246)
FDA (2869)
Featured Employer (13)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (240)
Gene editing (38)
Generative AI (8)
Gene therapy (85)
GLP-1 (175)
Government (917)
Guidances (14)
Healthcare (3873)
Huntington's disease (3)
IgA nephropathy (6)
Immunology and inflammation (23)
Indications (9)
Infectious disease (736)
Inflammatory bowel disease (46)
Influenza (11)
Intellectual property (23)
Interviews (34)
IPO (2037)
IRA (5)
Job creations (624)
Job search strategy (201)
Kidney cancer (2)
Labor market (7)
Layoffs (89)
Leadership (5)
Legal (882)
Liver cancer (15)
Lung cancer (84)
Lymphoma (39)
Machine learning (4)
Management (11)
Manufacturing (54)
MASH (23)
Medical device (1798)
Medtech (1800)
Mergers & acquisitions (3294)
Metabolic disorders (176)
Multiple sclerosis (22)
NASH (5)
Neurodegenerative disease (30)
Neuropsychiatric disorders (8)
Neuroscience (719)
NextGen: Class of 2025 (1275)
Non-profit (1398)
Northern California (639)
Now hiring (6)
Obesity (87)
Opinion (49)
Ovarian cancer (13)
Pain (18)
Pancreatic cancer (18)
Parkinson's disease (54)
Partnered (5)
Patents (45)
Patient recruitment (27)
Peanut (9)
People (18120)
Pharmaceutical (7)
Phase I (4956)
Phase II (7026)
Phase III (5811)
Pipeline (322)
Policy (24)
Postmarket research (663)
Preclinical (3229)
Press Release (33)
Prostate cancer (31)
Psychedelics (11)
Radiopharmaceuticals (48)
Rare diseases (111)
Real estate (1217)
Recruiting (15)
Regulatory (3900)
Reports (8)
Research institute (1025)
Resumes & cover letters (23)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (18)
Series A (60)
Series B (18)
Sickle cell disease (24)
Southern California (518)
Special edition (1)
Spinal muscular atrophy (66)
Sponsored (14)
Startups (1182)
State (1)
Stomach cancer (3)
Supply chain (9)
Tariffs (2)
The Weekly (2)
United States (5708)
Vaccines (138)
Venture capitalists (8)
Weight loss (37)
Women's health (7)
Worklife (2)
Date
Today (15)
Last 7 days (236)
Last 30 days (714)
Last 365 days (8278)
2025 (2628)
2024 (8873)
2023 (10132)
2022 (12901)
2021 (14124)
2020 (12488)
2019 (10044)
2018 (7704)
2017 (7862)
2016 (7585)
2015 (8166)
2014 (5962)
2013 (4759)
2012 (4885)
2011 (5149)
2010 (4329)
Location
Africa (162)
Alabama (12)
Alaska (4)
Arizona (32)
Arkansas (2)
Asia (7974)
Australia (1353)
California (1412)
Canada (526)
China (106)
Colorado (73)
Connecticut (72)
Delaware (35)
Europe (22064)
Florida (162)
Georgia (49)
Idaho (9)
Illinois (101)
India (2)
Indiana (54)
Iowa (2)
Japan (39)
Kansas (11)
Kentucky (4)
Louisiana (3)
Maine (38)
Maryland (175)
Massachusetts (1294)
Michigan (75)
Minnesota (61)
Missouri (21)
Montana (5)
Nebraska (6)
Nevada (14)
New Hampshire (14)
New Jersey (398)
New Mexico (21)
New York (523)
North Carolina (220)
North Dakota (2)
Northern California (639)
Ohio (68)
Oklahoma (6)
Oregon (19)
Pennsylvania (342)
Puerto Rico (2)
Rhode Island (14)
South America (196)
South Carolina (3)
Southern California (518)
Tennessee (19)
Texas (239)
Utah (68)
Virginia (32)
Washington D.C. (8)
Washington State (142)
Wisconsin (13)
145,335 Results for "ananda scientific".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain
October 15, 2024
·
2 min read
Business
SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics
September 4, 2024
·
3 min read
Pharm Country
ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)
ANANDA Scientific Inc. today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).
March 28, 2023
·
3 min read
Business
Cancer Research Institute Awards Ananda Goldrath, Ph.D., with the 2023 Frederick W. Alt Award
The Cancer Research Institute has awarded Ananda Goldrath, Ph.D., Executive Vice President and Director of the Allen Institute for Immunology, the 2023 Frederick W. Alt Award.
October 30, 2023
·
3 min read
Business
Dennis Wong Joins ANANDA Scientific’s Board of Directors
ANANDA Scientific Inc., a research-focused bio-pharmaceutical company, announced that Dennis Wong, President and CEO of Baxco Pharmaceutical Inc, has been appointed to ANANDA Scientific’s Board of Directors.
July 19, 2022
·
2 min read
Business
University of Nebraska Medical Center and ANANDA Scientific announce First Patient Enrolled in FDA-approved clinical trial for Post-Traumatic Stress Disorder (PTSD)
The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5 , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD).
March 14, 2023
·
3 min read
Business
Dennis Wong Joins ANANDA Scientific Inc. Board of Directors
ANANDA Scientific Inc ., a research-focused bio-pharmaceutical company, today announced that Dennis Wong , President and CEO of Baxco Pharmaceutical Inc, has been appointed to A NANDA Scientific’s Board of Directors.
July 19, 2022
·
2 min read
FDA
ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)
ANANDA Scientific Inc today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S.
November 30, 2022
·
2 min read
Biotech Beach
ANANDA Scientific Announces First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced the first patient enrolled in the clinical trial evaluating Nantheia™ ATL5 , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.
July 26, 2022
·
3 min read
Business
ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain
ANANDA Scientific Inc . today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology.
March 8, 2022
·
7 min read
1 of 14,534
Next
